Biogen
NEWS
Biogen’s Aduhelm was approved on June 7, 2021, for Alzheimer’s patients, and the controversy continues to grow.
Mirimus and Biogen, AavantiBio and Aldevron, Exscientia and GT Apeiron Therapeutics announced strategic partnerships this morning.
The FDA has historically tended to keep more contentious relationships with some companies private. But recently, the agency appears to be publicly scolding some biopharma companies.
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here’s a look at a few of the bay area biotech companies hiring now.
In its 2Q2021 Clinical Report, BioSpace highlights drugs that were greenlit for clinical studies, faced clinical and regulatory hurdles and some who saw regulatory wins.
The license and collaboration agreement center on orelabrutinib, an oral small molecule BTKi characterized by its high selectivity and the ability to cross the blood-brain barrier.
Adulhelm’s proposed price tag of $56,000 per patient per year is hardly the most expensive drug on the market, but controversy regarding packaging and pricing continues.
Acting commissioner of the U.S. FDA asked the independent Office of the Inspector General to investigate how the FDA and representatives of Biogen interacted prior to the FDA’s approval of the company’s Aduhelm (aducanumab) for Alzheimer’s disease.
The saga continues for Biogen’s Alzheimer’s drug Aduhelm as the U.S. Food and Drug Administration approved an updated label that emphasizes the disease stages for which the drug was approved.
JOBS
IN THE PRESS